Ovarian carcinosarcoma
MONDO:0003792A highly aggressive malignant neoplasm arising from the ovary. Morphologically, it is a high grade tumor, composed of carcinomatous and sarcomatous elements.
Also known as: MMMT of the ovary, carcinosarcoma of ovary, carcinosarcoma of the ovary, malignant mixed mesodermal Mullerian neoplasm of ovary, malignant mixed mesodermal Mullerian neoplasm of the ovary, malignant mixed mesodermal Mullerian tumor of ovary, malignant mixed mesodermal Mullerian tumor of the ovary, malignant mixed mesodermal Mullerian tumour of ovary
2857 clinical trials for this condition and its sub-types, 18 tagged with Ovarian carcinosarcoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Can a Two-Drug combo tame a rare and aggressive gynecologic cancer?
Disease control CompletedThis phase II trial is testing whether the chemotherapy drug eribulin, given alone or combined with the immunotherapy pembrolizumab, can help people with ovarian or uterine carcinosarcoma that has returned or progressed. The study aims to see if these treatments can shrink tumors…
Phase 2 • Sponsor: Australia New Zealand Gynaecological Oncology Group • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tested a new drug called RP-6306 in 28 people with advanced cancer that could not be cured. The goal was to see if adding RP-6306 to standard treatment helps shrink tumors and is safe. Researchers also looked for specific biomarkers to see if some patients respond bett…
Phase 2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New drug combo shows promise for resistant ovarian cancer
Disease control CompletedThis study tested a new drug called relacorilant combined with chemotherapy (nab-paclitaxel) in 178 women with ovarian, fallopian tube, or peritoneal cancer that came back and no longer responds to platinum-based treatments. The goal was to see if the combination helps keep the c…
Phase 2 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC